Management is deliberately reducing exposure to the 'overcrowded' sponsor finance market, citing an oversupply of capital and deteriorating underwriting standards among peers.

The portfolio has reached a record 83% allocation to senior secured specialty finance, prioritizing asset-based lending (ABL) with liquid collateral and active borrowing base monitoring.

The company maintains an intentional underweighting in the software sector (approximately 2% exposure) to avoid risks associated with technological obsolescence and artificial intelligence threats.

Performance stability is attributed to a multi-strategy approach that allows the firm to 'say no' to cash flow loans that do not meet conservative lending standards.

Asset-based lending originations nearly doubled year-over-year, driven by the complexity premium and high barriers to entry in collateral-heavy corporate financing.

The Life Sciences strategy remains focused on late-stage, revenue-generating companies with high FDA barriers to entry, avoiding the trend toward software-heavy healthcare IT.

Management views the current market as a 'sea change' for private credit, where manager performance will diverge based on credit discipline rather than just capital deployment.

Management expects to remain opportunistic in cash flow lending if market dislocations create more attractive risk-reward profiles later in 2026.

The company aims to potentially increase leverage toward the high end of its 1.25x target range through either individual investments or strategic platform acquisitions.

The Life Sciences pipeline is expected to reaccelerate as drug discovery timelines potentially shorten due to AI integration and a recovery in public bioscience valuations.

Management believes the company's earnings sensitivity to base rate declines is among the lowest in its peer group due to its diversified portfolio and lower allocation to cash flow loans compared to direct-lending-only strategies.

The company is actively evaluating inorganic growth opportunities, including portfolio acquisitions and hiring specialized lending teams to expand the ABL franchise.

The company reported zero investments on non-accrual status, with 100% of the portfolio performing at year-end.

Restructured PIK income remains de minimis at approximately 2% of total investment income, reflecting high cash-pay earnings quality.

A refinancing of the SSLP revolving credit facility reduced the interest rate spread by 75 basis points, enhancing future borrowing flexibility.

The weighted average yield declined to 11.6% from 12.2% due to Q4 base rate cuts and the timing of late-quarter investment fundings.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management is actively engaged in dialogues regarding potential platform acquisitions, often using initial lending relationships as a 'get to know you' phase.

While no deals are imminent, the quality of opportunities is high as market noise may force some players to seek exits or better access to capital.

Spreads in ABL have remained more resilient than cash flow markets due to a lack of new capital inflows and a smaller, more disciplined peer group.

Management believes the 'complexity premium' of ABL allows them to maintain attractive risk-adjusted returns even as base rates fluctuate.

Management reported no thematic increases in revolver usage or amendment requests, describing current issues as purely idiosyncratic.

The ABL strategy provides 'binoculars' into the economy through weekly monitoring of inventory turns and receivable collections, which currently show no broad signs of stress.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.